基于富马酸伏诺拉生的幽门螺杆菌根除治疗方案的现状  

Advances in the vonoprazan based therapy for Helicobacter pylori eradication

作　　者：陈珑 焦红梅[1] CHEN Long;JIAO Hong-mei(Department of Geriatrics,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院老年病内科,北京100034

出　　处：《中国临床药理学杂志》2022年第20期2506-2509,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：幽门螺杆菌感染是一个全球关注的问题。目前国际上多将四联治疗方案作为一线根除方案,但四联方案的副作用、细菌耐药率升高等问题被广泛关注。富马酸伏诺拉生是一种新型的钾离子竞争性酸阻断药,其具有起效迅速、抑酸充分、半衰期长等特点。目前已发表的部分研究表明基于富马酸伏诺拉生、阿莫西林、克拉霉素的三联根除方案耐受性良好,根除率与目前指南推荐的一线方案相当。随着克拉霉素耐药率逐年升高,最新的研究发现基于富马酸伏诺拉生、阿莫西林的二联根除方案疗效不劣于三联根除方案,且二联根除方案对肠道菌群影响更小。本文主要回顾近年来发表的基于富马酸伏诺拉生的幽门螺杆菌二联/三联根除方案疗效,并探讨其优势及可能的优化方案。Helicobacter pylori infection is a global concern.At present,the quadruple regimen is mostly used as the first-line eradication regimen in the world.However,the side effects of the quadruple regimen and the increased antimicrobial resistance to Helicobacter pylori have been widely concerned.Vonoprazan is a novel potassium-competitive acid blocker,which have characteristics of rapid action,long half-life and sufficient acid suppression.Previous studies have shown that the triple therapy based on vonoprazan,amoxicillin,and clarithromycin is well tolerated,and the eradication rate is comparable to the first-line regimen recommended by current guidelines.Recent studies have shown that the eradication rate of the dual therapy based on vonoprazon and amoxicillin is non-inferior to that of the vonoprazan based triple therapy.We therefore review the recent literatures on of the vonoprazan based dual/triple therapy for Helicobacter pylori eradication and discuss its advantages and possible optimization of the therapy.

关 键 词：幽门螺杆菌 二联疗法 三联疗法 富马酸伏诺拉生 阿莫西林 

分 类 号：R97[医药卫生—药品]